Home / Resources / Regulatory, Ethical and Patient Engagement Considerations for Plain Language Summaries

Regulatory, Ethical and Patient Engagement Considerations for Plain Language Summaries

White paper
Regulatory & Compliance
Regulatory, Ethical and Patient Engagement Considerations for Plain Language Summaries_hero image

The European Medicines Agency (EMA) and the US Food and Drug Administration differ on their approach to plain language summaries (PLS) of clinical trials.

Related products
Trial participants accessing TrialSummaries.com to learn more information about trials in plain language.
Trial Summaries
This user-friendly portal aggregates clinical trial results summaries across sponsors
Professionals accessing TrialScope Disclose to track trial compliancy and awareness of regulations.
TrialScope Disclose
Manage the complexity of clinical trial disclosure and the risk of noncompliance by automating data entry and reporting to registries
Sponsors accessing TrialScope Intelligence for regulations and requirements.
TrialScope Intelligence
A centralized, interactive repository of the critical regulatory knowledge needed for global clinical trial disclosure compliance

Related resources

Trial Summaries-Improving Patient-Centric Communications resource-card-thumbnail
JUL 01, 2023
White paper
Regulatory & Compliance

Trial Summaries Improving Patient-Centric Communications

The Pharma R&D Annual Review 2023 Supplement looks at new active substances (NASs), drugs launched onto the market for the first time, during 2022

Hands typing on a laptop device.
DEC 17, 2021
Article
Regulatory & Compliance

Considerations for Creating Plain Language Summaries

Writing plain language summaries can be a huge undertaking, especially if translations or a patient review panel are required. See what PLS should include.

View all resources
Darkened Qualified calendar. Please allow all cookies to use functionality.

To enable the booking feature, please enable all cookies in your browser.